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Introduction
Many therapeutic proteins, especially chimeric and
humanized anti-TNFalpha antibodies, produce an
unwanted immune response that can cause secondary
failure and infusion reactions [1]. The most widely
accepted hypothesis is the neutralization of the thera-
peutic agents by human anti-drug antibodies (ADA) [2].
Aim
An ambispective observational study was conducted to
determine the correlation between drug bioavailability,
immunogenicity, and loss of clinical efficacy in rheuma-
toid arthritis (RA) patients treated with infliximab and
adalimumab.
Patients and methods
Informed consents were obtained from all patients. Serum
samples were collected from 78 and 51 patients at baseline
and during the course of treatment over a year with inflixi-
mab and adalimumab, respectively. Concentrations of
ADAs and free drugs were measured with Promonitor®
test. Progression of the disease was evaluated using
Disease Activity Score (DAS28) index. European League
Against Rheumatism (EULAR) response criteria were used
to assess clinical response, and the population was classi-
fied at the end of the treatment year into responder
patients (ΔDAS28≥1.2) and non-responder patients
(ΔDAS28<1.2).
Results
47% and 20% of the patients developed antibodies against
infliximab and adalimumab, respectively. For both treat-
ments there is a strong inverse association between the
concentration of circulating drug and the presence of
antibodies (p<-0.001). The concentration of circulating
drug inversely correlates with DAS28 (p<-0.001). There
is also a direct correlation between the presence of ADAs
and the evolution of the disease measured through
DAS28. ADA concentrations were significantly higher in
non-responders compared to responder patients.
Conclusion
Regular monitoring of ADAs and circulating drug helps
to optimize the efficacy of biologicals, to improve
patient management and make a rational use of these
expensive therapies.
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